Lyell Immunopharma (LYEL) EPS (Weighted Average and Diluted) (2020 - 2026)
Lyell Immunopharma recorded quarterly EPS (Weighted Average and Diluted) of -$1.1 in Q1 2026, up 85.68% quarter-over-quarter from -$7.68 in Q4 2025, and up 68.93% year-over-year from -$0.65 in Q1 2025.
Lyell Immunopharma's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$1.1 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 68.93% year-over-year to -$1.1; the TTM figure through Mar 2026 stood at -$13.8 (up 44.82% YoY), while the FY2025 annual figure was -$16.06, up 38.77% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$1.1 for Q1 2026 at Lyell Immunopharma, up from -$7.68 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.03 in Q4 2022 to a low of -$17.97 in Q4 2023.
- A 5-year average of -$3.44 and a median of -$1.1 in 2026 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) surged 91.22% in 2022 and tumbled 59800.0% in 2023, its largest moves.
- Lyell Immunopharma's EPS (Weighted Average and Diluted) stood at -$0.03 in 2022, then sank by 59800.0% to -$17.97 in 2023, then climbed by 19.87% to -$14.4 in 2024, then soared by 46.67% to -$7.68 in 2025, then soared by 85.68% to -$1.1 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$1.1, -$7.68, and -$2.13 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -1.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.10 |
| Dec 31, 2025 | -7.68 |
| Sep 30, 2025 | -2.13 |
| Jun 30, 2025 | -2.89 |
| Mar 31, 2025 | -3.54 |
| Dec 31, 2024 | -14.40 |
| Sep 30, 2024 | -3.48 |
| Jun 30, 2024 | -3.59 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | -17.97 |
| Sep 30, 2023 | -0.20 |
| Jun 30, 2023 | -0.26 |
| Mar 31, 2023 | -0.27 |
| Dec 31, 2022 | -0.03 |
| Sep 30, 2022 | -0.28 |
| Jun 30, 2022 | -0.15 |
| Mar 31, 2022 | -0.28 |
| Dec 31, 2021 | -0.18 |
| Sep 30, 2021 | -0.20 |
| Jun 30, 2021 | -1.47 |
| Mar 31, 2021 | -3.19 |
| Dec 31, 2020 | -2.93 |